Epirubicin
- PDF / 141,853 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 124 Views
1
S
Anthracycline-associated cardiotoxicity: case report A 42-year-old woman developed anthracyclineassociated cardiotoxicity following treatment with epirubicin for breast cancer. The woman received 13 cycles of epirubicin 60 mg/m2 (cumulative dose of 780 mg/m2) in combination with cyclophosphamide every 3 weeks [route not stated]. She presented 5 weeks after her final dose with shortness of breath and was diagnosed with mild congestive heart failure and prescribed furosemide and enalapril. She was admitted 1 month later with dyspnoea, general fatigue, loss of appetite and orthopnoea. Physical examination showed a third heart sound, hypotension and tachycardia. Chest xray revealed cardiomegaly and pulmonary congestion. Echocardiography revealed a dilated and severely hypokinetic left ventricle. Her N-terminal pro-B-type natriuretic peptide was elevated and serum troponin T was positive. She was diagnosed with acute heart failure and treated accordingly. On hospital day 8, echocardiography showed left ventricular hypokinesis associated with mural thrombus and anticoagulant therapy was initiated. Despite treatment, she developed splenic thromboembolism on day 18. The woman’s cardiac function gradually recovered and she was discharged on day 73. After 1 year of follow-up her ECG findings had almost normalised, left-ventricular ejection fraction had recovered to 52% and she had resumed her full range of social and familial activities with no recurrence of breast cancer. Author comment: "We suspected, therefore, that epirubicin might have caused life-threatening heart failure due to [anthracycline-associated cardiotoxicity] in the present patient". Okura Y, et al. A case of epirubicin-associated cardiotoxicity progressing to lifethreatening heart failure and splenic thromboembolism. Internal Medicine 51: 1355-1360, No. 11, 2012. Available from: URL: http://dx.doi.org/10.2169/ 803076048 internalmedicine.51.6973 - Japan
0114-9954/10/1417-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 1 Sep 2012 No. 1417
Data Loading...
